STAT1 and neoplasm: The repression of AT3 tumor growth was accompanied by increases in STAT-1 signaling, the expression of STAT-1 target genes, such as Cxcl9 and Cd274, the recruitment of T cells, and the re-sensitization of otherwise resistant AT3 tumors to PD-1 immunotherapy.